Caribou Biosciences, Inc. Increase (Decrease) in Deferred Revenue
Caribou Biosciences, Inc. (CRBU) reported Increase (Decrease) in Deferred Revenue of -$2.47 million for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2022-08-09
- Caribou Biosciences, Inc. increase (decrease) in deferred revenue for the quarter ending 2022-06-30 was -$1.90M, a 203.89% decline year-over-year.
- Caribou Biosciences, Inc. increase (decrease) in deferred revenue for the quarter ending 2022-03-31 was -$572.00K, a 101.91% decline year-over-year.
- Caribou Biosciences, Inc. increase (decrease) in deferred revenue for the quarter ending 2021-12-31 was -$1.03M, a 1764.52% decline year-over-year.
- Caribou Biosciences, Inc. increase (decrease) in deferred revenue for the quarter ending 2021-09-30 was -$1.12M.
- Caribou Biosciences, Inc. increase (decrease) in deferred revenue for fiscal 2021 was $29.64M.
- Caribou Biosciences, Inc. increase (decrease) in deferred revenue for fiscal 2020 was -$605.00K.
- Caribou Biosciences, Inc. increase (decrease) in deferred revenue for fiscal 2019 was -$798.00K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2022-06-30 | -$1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$2.47M 10-Q · filed 2022-08-09 | -$3.50M derived: sum of 3 quarters · filed 2022-08-09 | -$4.62M derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | -$572.00K 10-Q · filed 2022-05-09 | -$1.60M derived: sum of 2 quarters · filed 2022-05-09 | -$2.73M derived: sum of 3 quarters · filed 2022-05-09 | -$899.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-12-31 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$2.15M derived: sum of 2 quarters · filed 2022-03-21 | -$327.00K derived: sum of 3 quarters · filed 2022-08-09 | $29.64M 10-K · filed 2022-03-21 |
| 2021-09-30 | -$1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $705.00K derived: sum of 2 quarters · filed 2022-08-09 | $30.67M 10-Q · filed 2021-11-09 | $30.73M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-06-30 | $1.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $31.79M 10-Q · filed 2022-08-09 | $31.85M derived: sum of 3 quarters · filed 2022-08-09 | $31.80M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $29.96M 10-Q · filed 2022-05-09 | $30.03M derived: sum of 2 quarters · filed 2022-05-09 | $29.97M derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | $62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $4.00K derived: sum of 2 quarters · filed 2022-03-21 | -$605.00K 10-K · filed 2022-03-21 | |
| 2020-09-30 | -$58.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$667.00K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | -$609.00K 10-Q · filed 2021-09-02 | |||
| 2019-12-31 | -$798.00K 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |